Clark Estates Inc. NY Has $2.76 Million Position in AMAG Pharmaceuticals, Inc. (AMAG)
Clark Estates Inc. NY boosted its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 25.0% during the second quarter, Holdings Channel reports. The fund owned 150,100 shares of the specialty pharmaceutical company’s stock after buying an additional 30,000 shares during the period. Clark Estates Inc. NY’s holdings in AMAG Pharmaceuticals were worth $2,762,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. boosted its position in AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after buying an additional 4,988,054 shares in the last quarter. Acadian Asset Management LLC boosted its position in AMAG Pharmaceuticals by 777.8% in the first quarter. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company’s stock worth $27,659,000 after buying an additional 1,086,937 shares in the last quarter. State Street Corp boosted its position in AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after buying an additional 1,082,366 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in AMAG Pharmaceuticals by 152.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock worth $23,129,000 after buying an additional 619,370 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its position in AMAG Pharmaceuticals by 2,768.3% in the first quarter. Perceptive Advisors LLC now owns 560,000 shares of the specialty pharmaceutical company’s stock worth $12,628,000 after buying an additional 540,476 shares in the last quarter.
Shares of AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 17.10 on Friday. The company’s market capitalization is $603.42 million. The firm’s 50-day moving average is $19.06 and its 200-day moving average is $20.82. AMAG Pharmaceuticals, Inc. has a 12-month low of $16.00 and a 12-month high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.18. The firm had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business’s revenue was up 24.3% compared to the same quarter last year. During the same period last year, the firm posted $1.45 earnings per share. On average, equities analysts predict that AMAG Pharmaceuticals, Inc. will post ($1.37) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://theolympiareport.com/2017/08/12/clark-estates-inc-ny-has-2-76-million-position-in-amag-pharmaceuticals-inc-amag.html.
A number of research firms recently issued reports on AMAG. Cantor Fitzgerald reiterated a “hold” rating and set a $23.00 price objective on shares of AMAG Pharmaceuticals in a research report on Tuesday, May 2nd. Jefferies Group LLC set a $40.00 price objective on shares of AMAG Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, April 20th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. Barclays PLC reiterated a “hold” rating and set a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. Finally, Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $28.09.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at $566,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.80% of the company’s stock.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.